Interleukin-1, inflammasomes and the skin

被引:147
作者
Feldmeyer, Laurence [1 ]
Werner, Sabine [2 ]
French, Lars E. [1 ]
Beer, Hans-Dietmar [1 ,2 ]
机构
[1] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland
[2] ETH, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
IL-1; Skin; Inflammasome; Caspase-1; Inflammation; IL-1-BETA-CONVERTING ENZYME; HUMAN KERATINOCYTES; TUMOR INVASIVENESS; ADAPTIVE IMMUNITY; MATURE IL-1-BETA; MICE DEFICIENT; INNATE; IL-1; ANTAGONIST; DISEASE;
D O I
10.1016/j.ejcb.2010.04.008
中图分类号
Q2 [细胞生物学];
学科分类号
071013 [干细胞生物学];
摘要
Interleukin (IL)-1 is a highly active and pleiotropic pro-inflammatory cytokine. Recent data impressively demonstrate that activating mutations in a human gene involved in prolL-1 beta maturation or loss-of-function mutations in the gene encoding IL-1 receptor antagonist (IL-1Ra) cause excessive activity of this cytokine. This can result in life-threatening systemic and local inflammation, particularly in the skin. Interestingly, experiments in mice revealed that epidermal keratinocytes can secrete large amounts of IL-1 alpha, which induces an inflammatory response in the skin. Secretion of IL-1 requires caspase-1 activity, and activation of the protease takes place in innate immune complexes, called inflammasomes. As keratinocytes express and activate caspase-1 in an inflammasome-dependent manner, these epithelial cells might be critically involved in the innate immunity of the skin. In this review we summarize the current knowledge on IL-1 and inflammasomes in the skin, particularly their involvement in skin homeostasis and disease. In addition, we discuss the hypothesis that keratinocytes are not only static bricks of the epidermal wall, but immunologically active cells critically involved in different (auto)-inflammatory (skin) diseases. (C) 2010 Elsevier GmbH. All rights reserved.
引用
收藏
页码:638 / 644
页数:7
相关论文
共 51 条
[1]
Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions [J].
Apte, RN ;
Krelin, Y ;
Song, XP ;
Dotan, S ;
Recih, E ;
Elkabets, M ;
Carmi, Y ;
Dvorkin, T ;
White, RM ;
Gayvoronsky, L ;
Segal, S ;
Voronou, E .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (06) :751-759
[2]
The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions [J].
Apte, Ron N. ;
Dotan, Shahar ;
Elkabets, Moshe ;
White, Malka R. ;
Reich, Eli ;
Carmi, Yaron ;
Song, Xiaping ;
Dvozkin, Tatyana ;
Krelin, Yakov ;
Voronov, Elena .
CANCER AND METASTASIS REVIEWS, 2006, 25 (03) :387-408
[3]
A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development [J].
Bar, D ;
Apte, RN ;
Voronov, E ;
Dinarello, CA ;
Cohen, S .
FASEB JOURNAL, 2004, 18 (01) :161-163
[4]
KERATINOCYTES AS INITIATORS OF INFLAMMATION [J].
BARKER, JNWN ;
MITRA, RS ;
GRIFFITHS, CEM ;
DIXIT, VM ;
NICKOLOFF, BJ .
LANCET, 1991, 337 (8735) :211-214
[5]
Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation [J].
Blumberg, Hal ;
Dinh, Huyen ;
Trueblood, Esther S. ;
Pretorius, James ;
Kugler, David ;
Weng, Ning ;
Kanaly, Suzanne T. ;
Towne, Jennifer E. ;
Willis, Cynthia R. ;
Kuechle, Melanie K. ;
Sims, John E. ;
Peschon, Jacques J. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2007, 204 (11) :2603-2614
[6]
Inflammasome-Mediated Disease Animal Models Reveal Roles for Innate but Not Adaptive Immunity [J].
Brydges, Susannah D. ;
Mueller, James L. ;
McGeough, Matthew D. ;
Pena, Carla A. ;
Misaghi, Amirhossein ;
Gandhi, Chhavi ;
Putnam, Chris D. ;
Boyle, David L. ;
Firestein, Gary S. ;
Horner, Anthony A. ;
Soroosh, Pejman ;
Watford, Wendy T. ;
O'Shea, John J. ;
Kastner, Daniel L. ;
Hoffman, Hal M. .
IMMUNITY, 2009, 30 (06) :875-887
[7]
TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity [J].
Creagh, Emma M. ;
O'Neill, Luke A. J. .
TRENDS IN IMMUNOLOGY, 2006, 27 (08) :352-357
[8]
Paradoxical roles of the immune system during cancer development [J].
de Visser, KE ;
Eichten, A ;
Coussens, LM .
NATURE REVIEWS CANCER, 2006, 6 (01) :24-37
[9]
Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation [J].
Dinarello, CA .
CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (04) :378-385
[10]
Interleukin-1β, interleukin-18, and the interleukin-1β converting enzyme [J].
Dinarello, CA .
MOLECULAR MECHANISMS OF FEVER, 1998, 856 :1-11